Actively Recruiting
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
Led by Rigshospitalet, Denmark · Updated on 2025-08-01
100
Participants Needed
1
Research Sites
160 weeks
Total Duration
On this page
Sponsors
R
Rigshospitalet, Denmark
Lead Sponsor
D
Danish Cancer Society
Collaborating Sponsor
AI-Summary
What this Trial Is About
A developed multimodal intervention targeting late effects in survivors of allogeneic hematopoietic stem cell transplantation (allo-HSCT) will be evaluated in a two-arm randomized controlled trial with an internal pilot phase.
CONDITIONS
Official Title
AlloCare - Support and Management of Late Effects After Allogeneic Hematopoietic Stem Cell Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Adult patients (age > 18 years) treated with myeloablative or non-myeloablative HSCT in outpatient follow-up without recurrent disease are eligible for inclusion.
You will not qualify if you...
- Patients with recurrence or subsequent malignancy requiring cancer treatment are excluded.
- Patients lacking access to email and the Internet are excluded.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Rigshospitalet
Copenhagen, Denmark, 2100
Actively Recruiting
Research Team
M
Mette Schaufuss Engedal, MSc
CONTACT
M
Mary Jarden
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here